Home > Healthcare > Medical Devices > Diagnostic Devices > Prostate-Specific Antigen Test Market

Prostate-Specific Antigen Test Market Share

Report ID: GMI7136
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Prostate-Specific Antigen Test Market Share

The prostate-specific antigen test industry is fragmented in nature, with companies competing to offer superior prostate-specific antigen test in this business space. Prominent players such as Abbott Laboratories Inc., Bio-Rad Laboratories, Inc., and Bayer AG hold a significant share in this market. These companies are diligently directing their efforts towards continuous test type innovation to gain substantial market share.

Some of the eminent market participants operating in the prostate-specific antigen test industry include:

Abbott Laboratories Inc.
AdvaCare Pharma
Bayer AG
Bio-Rad Laboratories, Inc.
Beckman Coulter, Inc.
FUJIREBIO is an H.U. Group company.
GE HealthCare.
Abcam plc.
Lomina AG.
Laboratory Corporation of America Holdings

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prostate-specific antigen test industry size was USD 3.9 billion in 2022 and is estimated to reach USD 8.8 billion by 2032 due to the ongoing research in the field of prostate cancer diagnostics and therapy.

The hospitals end-use segment was USD 1.5 billion in 2022 due to the surge in patient awareness regarding the importance of regular prostate cancer screening.

North America prostate-specific antigen test industry was worth USD 1.5 billion in revenue in 2022 due to demographic shifts, increased awareness, and rising technological advancements in the region.

Abbott Laboratories Inc., AdvaCare Pharma, Bayer AG, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., GE HealthCare, Abcam plc., Lomina AG, and Laboratory Corporation of America Holdings are some of the major prostate-specific antigen test companies.